Speaker illustration

Doctor Federico Felizzi

Novartis, Basel (Switzerland)

Indirect treatment comparison of ARNI vs SGLT2i in heart failure with reduced ejection fraction: a reconciliation of previous network meta-analyses

Event: Heart Failure 2023

Topic: Pharmacotherapy

Session: Chronic heart failure - pharmacotherapy 3

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb